CA-NETAPP
16.3.2022 13:02:09 CET | Business Wire | Press release
NetApp (NASDAQ: NTAP), a global, cloud-led, data-centric software company, together with Cisco (NASDAQ: CSCO), today announced the evolution of FlexPod with the introduction of FlexPod® XCS, providing one automated platform for modern applications, data and hybrid cloud services.
FlexPod is composed of pre-validated storage, networking, server technologies from Cisco and NetApp. The new FlexPod XCS platform is designed to accelerate the delivery of modern applications and data in a hybrid cloud environment. FlexPod XCS is the first and only hybrid cloud solution natively integrated across all three major public cloud providers. Additionally, organizations will have the option to use FlexPod-as-a-Service, a pay-as-you-grow pricing model for financial and operational flexibility.
“For years, FlexPod has been helping Presidio customers increase app performance, save software Capex, and decrease unplanned downtime incidents,” said Raphael Meyerowitz, vice president, Engineering at Presidio. “With FlexPod XCS, NetApp and Cisco are providing more flexibility, accessibility and scalability to our customers to deliver a seamless hybrid cloud experience.”
“It is great seeing Cisco and NetApp launching FlexPod XCS together in this hybrid cloud era,” said Jeffrey den Oudsten, Chief Technology Officer at Conscia Netherlands. “Standardization on FlexPod XCS brings rich technologies and huge benefits for us and our customers in various ways, with ability to deliver one point for billing, ordering, support and validated designs. Conscia is determined to facilitate the best hybrid cloud infrastructure for its customers, and together with Cisco and NetApp, we have the best-in-class technology partners helping us to deliver on that promise.”
FlexPod XCS simplifies hybrid cloud operations by increasing accessibility and scalability, extending the infrastructure from an on-premises and edge standard to the hybrid cloud. This new offering lays the groundwork for continued joint innovation that will bring new solutions to market for hybrid cloud, containers, and modern workloads.
FlexPod XCS provides a new set of capabilities to the FlexPod platform:
- Hybrid Cloud Connectivity: By extending organizations’ data fabric, customers gain the operational certainty of putting the right apps and data in the right place at the right time.
- Automation: Comprehensive infrastructure automation across all lifecycle phases using Cisco Intersight™ Cloud Orchestrator and NetApp automated scripts and workflows to simplify day-to-day IT operations including configuration, deployment, expansion, and infrastructure consumption and optimization.
- Visibility: Providing an enhanced and unified view of all FlexPod components through Cisco Intersight, enabling organizations to respond to their business needs more quickly with more intelligent resource decisions
- FlexPod-as-a-Service: Lowering initial costs for flexibility and tailoring purchasing options based on budgets and usage
- New Reference Architecture with NetApp Cloud Volumes ONTAP ® (CVO) instances in AWS: FlexPod XCS and ONTAP integration with automation via Cisco Intersight
FlexPod XCS also allows IT departments to gain new insights with full-stack visibility and customized automation capabilities that increase operational productivity. The new FlexPod-as-a-Service consumption model enables customers to have more financial and operational flexibility by aligning costs based on usage.
"Our strategic relationship with NetApp continues to create value for businesses through deep technology integration aimed at solving our customers' biggest challenges,” said Siva Sivakumar, Vice President, Cloud & Compute Product Management, Cisco. “FlexPod XCS powered by Cisco Intersight delivers key new capabilities for our customers such as automation, visibility and hybrid cloud operations into a single unified platform for modern apps, data, and hybrid cloud services.”
“We are proud of our continued innovation with Cisco as we expand FlexPod’s capabilities that solve for organizations’ unique business challenges,” said Mike Arterbury, Vice President, Hybrid Cloud Infrastructure & OEM Solutions at NetApp. “Building on our twelve-year partnership with Cisco, FlexPod XCS combines our best-in-class technologies to simplify the delivery of data and applications, enabling enterprises to run new services more efficiently at the edge, core or in the cloud.”
FlexPod® XCS is in preview for partners and customers and is expected to be generally available globally in mid-2022.
Additional Resources:
- NetApp Blog: FlexPod XCS Extends the FlexPod Infrastructure Standard to the Hybrid Cloud
- Cisco Blog: Cisco and NetApp introduce FlexPod XCS to simplify and accelerate customers’ hybrid cloud journeys
- Learn more about FlexPod XCS and the Cisco-NetApp Partnership
- FlexPod.com
About FlexPod
Trusted by thousands of customers across the globe, the enhanced FlexPod XCS platform brings a new level of visibility and automation that can help propel customers’ journey into hybrid cloud operations. Composed of prevalidated storage, networking and server technologies, and management software, FlexPod® XCS is designed to increase IT responsiveness to organizational needs providing intelligent insights to optimize costs and performance, support deployment decisions with cloud-like consumption models, and maintain existing configurations across FlexPod infrastructure. By simplifying the delivery of data and applications, enterprises have an advantage of running new services and workloads at the edge, core, or in the cloud.
FlexPod® XCS pricing is mapped to Cisco Intersight Advantage and Premier Tiers and current FlexPod pricing.
About NetApp
NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
Many of the products and features described herein remain in varying stages of development and will be offered on a when-and-if-available basis. The delivery timeline of these products and features is subject to change at the sole discretion of Cisco or NetApp, and neither Cisco nor NetApp will have liability for delay in the delivery or failure to deliver any of the products or features set forth in this document.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005269/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
